APVO
Aptevo Therapeutics Inc.NASDAQHealthcare$4.17+0.97%ClosedMarket Cap: $7.3M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.00
P/S
0.00
EV/EBITDA
0.37
DCF Value
$5,117.65
FCF Yield
-344.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-260.8%
ROA
-95.5%
ROIC
-119.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-6.0M | $-5.8M | $-159.33 | — |
| FY 2025 | $0.00 | -Infinity% | $-26.3M | $-26.0M | $-87.27 | — |
| Q3 2025 | $0.00 | NaN% | $-7.6M | $-7.5M | $-40.13 | — |
| Q2 2025 | $0.00 | NaN% | $-6.2M | $-6.2M | $-151.29 | — |
| Q1 2025 | $0.00 | NaN% | $-6.5M | $-6.4M | $-1,581.72 | — |
| Q4 2024 | $0.00 | -Infinity% | $-6.4M | $-6.3M | $-1,558.04 | — |
| FY 2024 | $0.00 | -Infinity% | $-24.6M | $-24.1M | $-31,458.00 | — |
| Q3 2024 | $0.00 | NaN% | $-5.2M | $-5.1M | $-6,441.29 | — |
| Q2 2024 | $0.00 | NaN% | $-6.0M | $-5.9M | $-22,262.00 | — |
| Q1 2024 | $0.00 | -Infinity% | $-7.0M | $-6.8M | $-132,553.00 | — |
| Q4 2023 | $0.00 | NaN% | $-6.4M | $-5.9M | $-177,705.00 | — |
| FY 2023 | $0.00 | NaN% | $-28.9M | $-17.4M | $-834,044.00 | — |